MX2023013492A - Moduladores de los receptores acoplados a proteinas g. - Google Patents
Moduladores de los receptores acoplados a proteinas g.Info
- Publication number
- MX2023013492A MX2023013492A MX2023013492A MX2023013492A MX2023013492A MX 2023013492 A MX2023013492 A MX 2023013492A MX 2023013492 A MX2023013492 A MX 2023013492A MX 2023013492 A MX2023013492 A MX 2023013492A MX 2023013492 A MX2023013492 A MX 2023013492A
- Authority
- MX
- Mexico
- Prior art keywords
- chemical entities
- glp
- gipr
- disorder
- disease
- Prior art date
Links
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title 1
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 abstract 4
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 4
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 4
- 150000005829 chemical entities Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 abstract 3
- 230000008484 agonism Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Holo Graphy (AREA)
- Gyroscopes (AREA)
- Amplifiers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188342P | 2021-05-13 | 2021-05-13 | |
| PCT/US2022/029305 WO2022241287A2 (en) | 2021-05-13 | 2022-05-13 | Modulators of g-protein coupled receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013492A true MX2023013492A (es) | 2024-02-29 |
Family
ID=82019613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013492A MX2023013492A (es) | 2021-05-13 | 2022-05-13 | Moduladores de los receptores acoplados a proteinas g. |
Country Status (20)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| KR20240007251A (ko) * | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| KR20250140132A (ko) * | 2023-01-18 | 2025-09-24 | 상하이 민웨이 바이오테크놀로지 씨오 엘티디 | 삼중 활성을 갖는 융합 단백질 및 그 용도 |
| EP4716545A1 (en) * | 2023-05-21 | 2026-04-01 | Carmot Therapeutics Inc. | Treatment of adults with overweight or obesity with or without weight-related comorbidities |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2026030653A1 (en) | 2024-07-31 | 2026-02-05 | Carmot Therapeutics Inc. | Synthesis of an intermediate and its use for the preparation of glp-1r/gipr agonists |
| WO2026027650A1 (en) | 2024-08-02 | 2026-02-05 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-(3-cyano-5-fluorophenyl)-2-methyl-propionic acid |
| TW202620036A (zh) | 2024-09-27 | 2026-05-16 | 美商卡默療法股份有限公司 | 肽酪胺酸-酪胺酸(pyy)類似物及glp-1r促效劑之組合療法 |
| WO2026092581A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata |
| WO2026092580A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases |
| WO2026099325A1 (en) * | 2024-11-08 | 2026-05-15 | F. Hoffmann-La Roche Ag | X-β-ALA-GLU(OTBU)-GLY TETRAMER AND ITS USE IN SPPS SYNTHESIS |
| WO2026112366A1 (en) * | 2024-11-20 | 2026-05-28 | Carmot Therapeutics Inc. | Treatment of steatotic liver disease associated with metabolic dysfunction |
| WO2026119942A1 (en) * | 2024-12-05 | 2026-06-11 | F. Hoffmann-La Roche Ag | Synthesis of a peptide including stepwise sidechain preparation |
| WO2026119946A1 (en) * | 2024-12-05 | 2026-06-11 | F. Hoffmann-La Roche Ag | Spps synthesis of a peptide with bsmoc-lys building block |
| WO2026119941A1 (en) * | 2024-12-05 | 2026-06-11 | F. Hoffmann-La Roche Ag | Spps synthesis of a peptide comprising a fatty acid side chain |
| WO2026125207A1 (en) * | 2024-12-09 | 2026-06-18 | F. Hoffmann-La Roche Ag | Process for the preparation of a x-beta-ala-glu(otbu)-gly tetramer by lpps and its use in spps synthesis |
| WO2026131797A2 (en) | 2024-12-18 | 2026-06-25 | F. Hoffmann-La Roche Ag | Process for the preparation of a fatty acid compound |
| WO2026153900A1 (en) | 2025-01-15 | 2026-07-23 | F. Hoffmann-La Roche Ag | Process for the preparation of a bsmoc-lys fatty acid compound |
| CN119930843B (zh) * | 2025-01-22 | 2025-12-30 | 北京康乐卫士生物技术股份有限公司 | 具有glp和gip双重活性的融合蛋白及其应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| AU2610899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| EP1137667B1 (en) | 1998-12-07 | 2004-11-17 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Analogues of glp-1 |
| CN1364167A (zh) | 1999-02-26 | 2002-08-14 | 阿瑞那制药公司 | G蛋白偶联受体6的小分子调节剂 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1235618A2 (en) | 1999-09-07 | 2002-09-04 | Conjuchem, Inc. | Bioconjugation in vivo to pulmonary or blood components |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| GB0325644D0 (en) | 2003-11-04 | 2003-12-10 | Avidex Ltd | Immuno ihibitory pyrazolone compounds |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| CA2607566A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| JP5399244B2 (ja) | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素5員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트 |
| CN103221404B (zh) | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| US20120021979A1 (en) | 2010-06-24 | 2012-01-26 | Vanderbilt University | GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| CA3134906A1 (en) | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| US20150087586A1 (en) | 2012-03-29 | 2015-03-26 | Cebix, Inc. | Pegylated c-peptide |
| CN104884056A (zh) | 2012-11-12 | 2015-09-02 | 雷德伍德生物科技股份有限公司 | 用于制备缀合物的化合物和方法 |
| JP6548579B2 (ja) | 2012-12-06 | 2019-07-24 | ヴィクトリア リンク リミテッド | コンジュゲート化合物 |
| US9766239B2 (en) | 2013-03-13 | 2017-09-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Synbodies for detection of human norovirus |
| CN105555756B (zh) | 2013-06-28 | 2018-12-07 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| WO2015031268A1 (en) | 2013-08-26 | 2015-03-05 | Arizona Board Of Regents On Behalf Of Arizona State University | High affinity synbodies for influenza |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| CN108271356A (zh) * | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| EP3218414A1 (en) | 2014-11-14 | 2017-09-20 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| GB2551945B (en) | 2015-12-18 | 2021-09-08 | Heptares Therapeutics Ltd | Novel GLP-1 receptor agonist peptides |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| MX2020009950A (es) * | 2018-03-23 | 2021-04-28 | Carmot Therapeutics Inc | Moduladores de receptores acoplados a proteina g. |
| TWI799680B (zh) | 2019-01-29 | 2023-04-21 | 美商美國禮來大藥廠 | 製備gip/glp1雙重促效劑之方法 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型glp-1/gip雙重促效劑 |
| KR20220050820A (ko) | 2020-10-16 | 2022-04-25 | 한미약품 주식회사 | Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물 |
| CN116171164A (zh) | 2020-10-17 | 2023-05-26 | 太阳医药工业有限公司 | Glp-1/gip双重激动剂 |
| CN114617956B (zh) | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| CN116635050A (zh) | 2020-12-24 | 2023-08-22 | 韩美药品株式会社 | 对胰高血糖素、glp-1和gip受体全部具有活性的新型三重激动剂及其用途 |
| KR20240007251A (ko) * | 2021-05-13 | 2024-01-16 | 카모트 테라퓨틱스, 인크. | G-단백질 결합 수용체의 조절제 |
| IL310644A (en) | 2021-08-23 | 2024-04-01 | Lilly Co Eli | Compounds and Methods for Liquid Phase Synthesis |
| EP4410827A4 (en) | 2021-09-02 | 2026-04-29 | Sunshine Lake Pharma Co Ltd | GLP-1/GIP Dual Target Fusion Polypeptide and Protein and Their Applications |
| EP4436991A1 (en) | 2021-11-22 | 2024-10-02 | Sun Pharmaceutical Industries Limited | Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof |
-
2022
- 2022-05-13 KR KR1020237042878A patent/KR20240007251A/ko active Pending
- 2022-05-13 MX MX2023013492A patent/MX2023013492A/es unknown
- 2022-05-13 IL IL308392A patent/IL308392A/en unknown
- 2022-05-13 EP EP22729907.0A patent/EP4337682A2/en active Pending
- 2022-05-13 PE PE2023003051A patent/PE20240890A1/es unknown
- 2022-05-13 AU AU2022272251A patent/AU2022272251A1/en active Pending
- 2022-05-13 CA CA3220005A patent/CA3220005A1/en active Pending
- 2022-05-13 US US17/744,540 patent/US12281149B2/en active Active
- 2022-05-13 JP JP2023569936A patent/JP2024517942A/ja active Pending
- 2022-05-13 GE GEAP202416419A patent/GEAP202416419A/en unknown
- 2022-05-13 CR CR20230530A patent/CR20230530A/es unknown
- 2022-05-13 CN CN202280048710.4A patent/CN117980325A/zh active Pending
- 2022-05-13 WO PCT/US2022/029305 patent/WO2022241287A2/en not_active Ceased
- 2022-05-13 BR BR112023023559A patent/BR112023023559A2/pt unknown
- 2022-05-13 TW TW111118138A patent/TW202313666A/zh unknown
-
2023
- 2023-11-09 DO DO2023000247A patent/DOP2023000247A/es unknown
- 2023-11-10 CL CL2023003369A patent/CL2023003369A1/es unknown
- 2023-11-13 JO JOJO/P/2023/0291A patent/JOP20230291A1/ar unknown
- 2023-11-21 CO CONC2023/0015805A patent/CO2023015805A2/es unknown
- 2023-12-13 EC ECSENADI202393673A patent/ECSP23093673A/es unknown
-
2024
- 2024-07-18 US US18/777,223 patent/US20240383960A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23093673A (es) | 2024-01-31 |
| GEAP202416419A (en) | 2024-03-25 |
| WO2022241287A2 (en) | 2022-11-17 |
| CA3220005A1 (en) | 2022-11-17 |
| BR112023023559A2 (pt) | 2024-02-06 |
| PE20240890A1 (es) | 2024-04-24 |
| US12281149B2 (en) | 2025-04-22 |
| EP4337682A2 (en) | 2024-03-20 |
| DOP2023000247A (es) | 2024-03-28 |
| WO2022241287A3 (en) | 2022-12-29 |
| CO2023015805A2 (es) | 2023-12-11 |
| CN117980325A (zh) | 2024-05-03 |
| AU2022272251A1 (en) | 2023-11-16 |
| CR20230530A (es) | 2024-02-19 |
| TW202313666A (zh) | 2023-04-01 |
| IL308392A (en) | 2024-01-01 |
| JOP20230291A1 (ar) | 2023-11-13 |
| US20240383960A1 (en) | 2024-11-21 |
| CL2023003369A1 (es) | 2024-05-17 |
| US20230151074A1 (en) | 2023-05-18 |
| KR20240007251A (ko) | 2024-01-16 |
| JP2024517942A (ja) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022241287A3 (en) | Modulators of g-protein coupled receptors | |
| MY205468A (en) | Modulators of g-protein coupled receptors | |
| Hirabayashi et al. | Discovery of PACAP and its receptors in the brain | |
| Isaac | Clonidine in the central nervous system: site and mechanism of hypotensive action | |
| Pelayo et al. | Inhibition of neuronal uptake reduces the presynaptic effects of clonidine but not of α-methylnoradrenaline on the stimulation-evoked release of 3H-noradrenaline from rat occipital cortex slices | |
| Sherman et al. | Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression | |
| DE602005011617D1 (de) | Hochaffiner ny-eso-t-zellen-rezeptor | |
| PE20221273A1 (es) | Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos | |
| CO5150232A1 (es) | METODO Y COMBINACION QUE UTILIZAN (+) NORCISAPRIDA EN COMBINACION CON INHIBIDORES DE BOMBA DE PROTONES O ANTAGONISTAS DEL RECEPTOR H[sub 2] | |
| MA43468A1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| WO2021016571A3 (en) | Methods of treating antibody-mediated disorders with fcrn antagonists | |
| CO6210755A2 (es) | Antagonistas del dr6 y usos de los mismos en le tratamiento de transtornos neurologicos | |
| On et al. | Evolution of parathyroid hormone receptor family and their ligands in vertebrate | |
| PH12022552562A1 (en) | Qd dosing of gip receptor agonist peptide compounds and uses thereof | |
| Fieber | Neurotransmitters and neuropeptides of invertebrates | |
| Burnstock | Expanding field of purinergic signaling | |
| Malmström et al. | Neuropeptide Y accounts for sympathetic vasoconstriction in guinea-pig vena cava: evidence using BIBP 3226 and 3435 | |
| Boonyaviroj et al. | α-Adrenergic stimulants, prostaglandins and catecholamine release from the adrenal gland in vitro | |
| Jouneaux et al. | Gs mediates hormonal inhibition of the calcium pump in liver plasma membranes. | |
| Feuerstein et al. | Characterization of the α2-adrenoceptor subtype, which functions as α2-autoreceptor in human neocortex | |
| Donald et al. | Neural regulation of the pulmonary vasculature in a semi-arboreal snake, Elaphe obsoleta | |
| Crosson et al. | Response to prejunctional adenosine receptors is dependent on stimulus frequency | |
| Sabbatini et al. | C-type natriuretic peptide stimulates pancreatic exocrine secretion in the rat: role of vagal afferent and efferent pathways | |
| Martire et al. | Neuropeptide Y interaction with the adrenergic transmission line: a study of its effect on alpha-2 adrenergic receptors | |
| Seong et al. | 5-Hydroxytryptamine modulation of electrically induced twitch responses of mouse vas deferens: involvement of multiple 5-hydroxytryptamine receptors. |